Insider Buying: Neuronetics (NASDAQ:STIM) Major Shareholder Buys 450,000 Shares of Stock

March 21, 2026 by InsiderTrades.com

Key Points

Major insider buying: Jorey Chernett bought roughly 1.59 million Neuronetics shares across March 17–19 (including 450,000 at $1.33 on March 19), increasing his direct stake to 8,573,804 shares — a 5.54% rise that signals insider confidence.
Operationally the company modestly beat Q4 expectations (EPS -$0.10 vs. -$0.12 est.; revenue $41.8M vs. $40.8M est.) but remains unprofitable with a negative return on equity and net margin, and analysts forecast continued losses for the fiscal year.
Market and analyst response is mixed: consensus rating is a Hold with a $3 price target, Canaccord trimmed its target from $7 to $3 while keeping a Buy, and the stock experienced short-term sell pressure (~5% intraday); institutional investors own about 53.6% of the shares.

Neuronetics, Inc. (NASDAQ:STIM - Get Free Report) major shareholder Jorey Chernett purchased 450,000 shares of the business's stock in a transaction dated Thursday, March 19th. The shares were purchased at an average price of $1.33 per share, for a total transaction of $598,500.00. Following the acquisition, the insider directly owned 8,573,804 shares of the company's stock, valued at $11,403,159.32. This trade represents a 5.54% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.

Jorey Chernett also recently made the following trade(s):

On Wednesday, March 18th, Jorey Chernett acquired 607,400 shares of Neuronetics stock. The stock was purchased at an average cost of $1.35 per share, with a total value of $819,990.00.
On Tuesday, March 17th, Jorey Chernett acquired 531,000 shares of Neuronetics stock. The shares were purchased at an average price of $1.16 per share, for a total transaction of $615,960.00.

Neuronetics Price Performance

Shares of NASDAQ:STIM opened at $1.45 on Friday. The company's fifty day moving average is $1.60 and its two-hundred day moving average is $2.03. The company has a quick ratio of 2.09, a current ratio of 2.02 and a debt-to-equity ratio of 2.51. Neuronetics, Inc. has a 12-month low of $0.80 and a 12-month high of $5.05. The company has a market cap of $100.45 million, a P/E ratio of -2.46 and a beta of 0.87.

Neuronetics (NASDAQ:STIM - Get Free Report) last released its earnings results on Tuesday, March 17th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.02. Neuronetics had a negative return on equity of 121.26% and a negative net margin of 26.15%.The company had revenue of $41.78 million during the quarter, compared to analyst estimates of $40.84 million. Equities analysts expect that Neuronetics, Inc. will post -1.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Neuronetics from a "hold" rating to a "sell" rating in a research report on Saturday. Canaccord Genuity Group lowered their price objective on shares of Neuronetics from $7.00 to $3.00 and set a "buy" rating on the stock in a research report on Thursday. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Neuronetics in a research note on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $3.00.

View Our Latest Analysis on STIM

Key Headlines Impacting Neuronetics

Here are the key news stories impacting Neuronetics this week:

Positive Sentiment: Major insider buying: Jorey Chernett (a major shareholder) increased his stake with multiple purchases over March 17–19 totaling roughly 1.59M shares across filings, boosting ownership and signaling insider confidence. SEC Form 4 filing Investing.com coverage
Positive Sentiment: Q4 results modestly beat expectations: EPS of ($0.10) vs. (~$0.12) est. and revenue $41.8M vs. $40.8M expected — a near‑term operational positive but the company remains unprofitable. Earnings call transcript
Neutral Sentiment: Mixed analyst and institutional profile: MarketBeat notes one Buy and one Sell rating, a consensus “Hold,” active institutional turnover, and wide variance in targets — underlines divergent views and liquidity sensitivity for this small‑cap stock. MarketBeat coverage
Negative Sentiment: Price‑target reduction from Canaccord: Canaccord cut its target from $7 to $3 (still a Buy), narrowing perceived upside and likely weighing on sentiment despite the maintained rating. Benzinga report
Negative Sentiment: Short‑term sell pressure / headline reaction: AAII and other outlets highlighted a multi‑percent intraday decline (around 5%), attributing it to the mix of analyst action, profit‑taking after recent moves, and the company’s continued negative margins and leverage. AAII article

Hedge Funds Weigh In On Neuronetics

Hedge funds have recently added to or reduced their stakes in the company. Madryn Asset Management LP bought a new position in Neuronetics during the fourth quarter valued at approximately $25,497,000. Vanguard Group Inc. grew its position in Neuronetics by 3.3% in the third quarter. Vanguard Group Inc. now owns 2,832,118 shares of the company's stock worth $7,732,000 after acquiring an additional 89,504 shares in the last quarter. UBS Group AG grew its position in Neuronetics by 20.4% in the fourth quarter. UBS Group AG now owns 2,607,047 shares of the company's stock worth $3,598,000 after acquiring an additional 442,216 shares in the last quarter. Lane Generational LLC acquired a new position in shares of Neuronetics during the 4th quarter worth $2,353,000. Finally, Balyasny Asset Management L.P. increased its stake in shares of Neuronetics by 6.5% during the 2nd quarter. Balyasny Asset Management L.P. now owns 1,509,099 shares of the company's stock worth $5,267,000 after purchasing an additional 92,048 shares during the last quarter. Institutional investors and hedge funds own 53.59% of the company's stock.

About Neuronetics

(Get Free Report)

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company's flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.